Results 141 to 150 of about 122,879 (343)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

The Chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma [PDF]

, 2000
Xiu-Min Li, Chih-Kang Huang, Téngfēi Zhāng, Ariel Teper, Kamal Srivastava, Brian Schofield, Hugh A. Sampson   +6 more
openalex   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang, Xiaofei Zhao, Taixin Wang, Luning Xiong, Xiujuan Liu, Jing Pan, Wen Yin, Chao Zhang, Jining Dong, Kexin Zhao   +9 more
wiley   +1 more source

Clinical observation on chinese herbal medicine in treatment of long-term insomnia [PDF]

, 2000
David Wang, Charlie Changli Xue, Noel Lim, Woei‐Jia Jiang, Jennifer R. Jamison   +4 more
openalex   +1 more source

Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024

Drug Testing and Analysis, EarlyView.
Scenarios of drug exposure and administration as well as detection assays for drugs and methods of sports doping published between 2023 and 2024 are critically reviewed and evaluated in context with the Prohibited List 2024 as established by the World Anti‐Doping Agency.
Mario  Thevis, Tiia  Kuuranne, Hans  Geyer   +2 more
wiley   +1 more source

Clinical observation on treatment of tubal pregnancy by chinese herbal medicine combined with tubal intubation administration of methotrexate under uteroscope [PDF]

, 2000
Qingsong Ye, Zhimian Zhang, Yumei Jiang, Luo Bi, Yiwen Li, Hongmei Ju, Yajuan Ge   +6 more
openalex   +1 more source

Identification and Investigation of the Intrinsic Receptor Activation Potential and Metabolization of the New Oxo‐Pyridyl Synthetic Cannabinoid Receptor Agonist CH‐FUBBMPDORA

Drug Testing and Analysis, EarlyView.
Another Chinese generic ban‐evading SCRA, CH‐FUBBMPDORA, has emerged. This study reports its first identification in Europe, its analytical characterization (NMR, Raman, FTIR, GC–MS, and HRMS), its cannabinoid activation potential in a βarr2 recruitment assay, and its metabolization profile.
Marie H. Deventer, Maria Carmela Emanuele, Brianna N. Stang, Katleen Van Uytfanghe, Jessica Masson, Xavier Bouvot, Catherine Lamoureux, Alessandro Proposito, Fabiano Reniero, Margaret V. Holland, Alex J. Krotulski, Luisa Mannina, Christophe P. Stove, Claude Guillou   +13 more
wiley   +1 more source

Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China

ESC Heart Failure, EarlyView.
Abstract Aims The study aimed to analyse the cost‐utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective. Methods and results From the perspective of the healthcare payer, a Markov model was established to estimate the cost‐utility of adding QLQX ...
Lu Wang, Yinglin Wang, Quan Zhao
wiley   +1 more source

The Dissemination and Development of Chinese Medicine in Pakistan

Chinese Medicine and Culture
. The article focuses on the dissemination and development of Chinese medicine in Pakistan. Religious records show that Chinese medicine was introduced to Pakistan as early as 1,400 years ago, while Hijama (Chinese cupping) was used by Prophet Hazrat ...
Jie LIN, Saeed Saboor, Jin LU
doaj   +1 more source